Cardio³ Biosciences

Company Profile in 2008

Cardio³ BioSciences is a medium stage biomedical company focused on regenerating heart muscle for patients with heart disease.

› Focus on the first cause of death in adult populations and a large unmet clinical need
› Leading edge stem cell biology research based on Mayo Clinic Technology
› A target community of practice demanding curative intervention

C-Cure™ is a proprietary product made from autologous stem cells guided to cardiac lineage. C-Cure is based on a process developed at the Mayo Clinic (Rochester, MN, USA). Use of a proprietary combination of growth factors and cytokines leads to a very reproducible and well defined cell population that expresses certain specific cardiac development markers. Once this population is expanded, the results achieved after implantation of human cardiac patient cells in an immunocompromised ischemic chronic heart failure animal model lead to near total recovery of ejection fraction as well as significant improvement in all other functional criteria. Non committed mesenchymal cells only improve cardiac function marginally. C-Cure™ is in final phases of pre-clinical testing with a first human implant scheduled for Q2 2008.
C-Cure™ has been tested in pre-clinical models of non-ischemic heart failure and is leading to similar benefits to the ischemic model.

C-Cath™ is a catheter with a specific needle design that allows superior cell retention. Current cell retention rates for epicardial injections are limited to around 10% while endocardial injection retention rates hover around 4%. While those retention rates could be overcome by increasing the delivered dose, the cost of the product could be dramatically reduced by enhancing those rates. In addition, a future development of this catheter will integrate imaging techniques that will allow accurate positioning of the injections in areas likely to induce the greatest clinical benefits.

A research pipeline for next generation cell based productsC-Cure™ has been tested in pre-clinical models of non-ischemic heart failure and is leading to similar benefits to the ischemic model.